Perceived barriers to paracetamol (acetaminophen) prescribing, especially following rofecoxib withdrawal from the market

Clinical Rheumatology

Volumn 28, Issue 5, 2009, Pages 509-519

  Barozzi, Nadia ^a   Tett, Susan E ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

COX 2 inhibitors; Osteoarthritis; Paracetamol; Prescribing barriers; Rofecoxib

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; MELOXICAM; PARACETAMOL; ROFECOXIB;

ACCESS TO INFORMATION; ADULT; AGED; ALTERNATIVE MEDICINE; ARTICLE; AUSTRALIA; CHRONIC PAIN; CLINICAL ARTICLE; CONSUMER ATTITUDE; DATA ANALYSIS; DRUG EFFICACY; DRUG INFORMATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; ELDERLY CARE; FEMALE; GENERAL PRACTITIONER; HUMAN; INDIVIDUALIZATION; INFORMATION PROCESSING; INTERNET; INTERPERSONAL COMMUNICATION; KNOWLEDGE BASE; MALE; MEDICAL DECISION MAKING; OSTEOARTHRITIS; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT DECISION MAKING; PHARMACIST ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; SELF MEDICATION; SEMI STRUCTURED INTERVIEW; TELECONSULTATION; UNSPECIFIED SIDE EFFECT;

ACETAMINOPHEN; ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, NON-NARCOTIC; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHEMISTRY, PHARMACEUTICAL; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; FOCUS GROUPS; HUMANS; LACTONES; MALE; MIDDLE AGED; OSTEOARTHRITIS; PERCEPTION; PHYSICIAN'S PRACTICE PATTERNS; PRODUCT SURVEILLANCE, POSTMARKETING; SULFONES;

EID: 64449086545     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-008-1077-8     Document Type: Article

References (35)

1. Woolf AD, Pfleger B (2003) Burde of major musculoskeletal conditions. Bull WHO 81(9):646-656
2. Australian Institute of Health and Welfare (2006) Australia's health. AIHW, Canberra (cat no. 73)
3. Therapeutic Guidelines: Rheumatology Writing Group (2006) Therapeutic guidelines: Rheumatology. Therapeutic Guidelines, Melbourne
4. Therapeutic Guidelines: Analgesic Writing Group (2002) Therapeutic guidelines: Analgesic, 4th edn. Therapeutic Guidelines, Melbourne
5. Australian and New Zealand College of Anaesthetists (2005) Acute pain management: Scientific evidence, 2nd edn. Faculty of Pain Medicine
6. Altman R, Hochberg M, Moskowitz R, Schnitzer T (2000) Recommendations for the medical management of osteoarthritis of the hip and knee. Arthritis Rheum 43:1905-1915
7. European League Against Rheumatism (2003) EULAR Recommendations 2003: An evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 62:1145-1155
8. Gastroenterological Society of Australia (GESA) (2004) NSAID therapy - maximizing the benefit, minimizing the risk. www.gesa.org.au/ members_booklets/nsaid/NSAIDTherapy.pdf. Cited 12 May 2007
9. Courtney P, Doherty M (2002) Key questions concerning paracetamol and NSAIDs for osteoarthritis. Ann Rheum Dis 61:767-773
10. Barozzi N, Tett S (2006) How rofecoxib withdrawal influence overall non selective non steroidal anti-inflammatory drugs and paracetamol prescription in Australia? National Medicine Symposium, Canberra
11. Barozzi N, Tett S (2007) What happened to the prescribing of other COX-2 inhibitors, paracetamol and non-steroidal anti-inflammatory drugs when rofecoxib was withdrawn in Australia? Pharmacoepidemiol Drug Saf 16(11):1184-1191
12. Lanas A (2005) Review article: Recommendations for the clinical management of patients taking non-steroidal anti-inflammatory drugs - a gastroenterologist's prospective. Aliment Pharmacol Ther 1:16-19
13. National Prescribing Service (2007) Prexige (Lumiracoxib) withdrawn: releases. http://www.nps.org.au/site.php?page=2&content=/resources/ content/prexige_withdrawn_rel.html. Cited 15 Sept 2007
14. Food and Drug Administration (FDA) (2004). FDA Public Health Advisory: Safety of Vioxx. www.fda.gov/cder/drug/infopage/vioxx/PHA_vioxx.htm. Cited 12 May 2007
15. National Prescribing Service (NPS) (2004). Switching patients from Vioxx. http://www.nps.org.au/resources/content/ nps_factsheet_vioxx_20041001.pdf. Cited 5 May 2007
16. National Prescribing Service (2005) Principles of evaluating new drugs. NPS News 43
17. National Prescribing Service (2007) NPS issues prescribing advice following Lumiracoxib withdrawal. http://www.nps.org.au/resources/ content/Prexige_Media_Release_HP.pdf. Cited 17 Sept 2007
18. Kelman CW, Pearson SA, Day R, Holman C, Kliewer EV, Henry DA (2007) Evaluating medicines: Let's use all the evidence. Med J Aust 186(5):249-252
19. Fung M, Thornton A, Mybeck K, Hsiao-Hui J, Hornbuckle K, Muniz E (2001) Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets'1960 to 1999* Drug Inf J 35:293-317
20. Avorn J (2004) Powerful medicines. The benefits, risks, and costs of prescription drugs. Knopf, New York
21. Langton P, Hankey G, Eikelboom J (2004) Cardiovascular safety of rofecoxib (Vioxx): Lessons learned and unanswered questions. Med J Aust 181(10):525-526
22. Psaty B, Furberg C (2005) COX-2 inhibitors - lessons in drug safety. N Engl J Med 352(11):1133-1135
23. Miller E, MacKeigan L, Rosser W, Marshman J (1999) Effects of perceived patient demand on prescribing anti-infective drugs. Can Med Ass J 161:139-142
24. Spence M, Teleki S, Cheetham C (2002) Direct-to-consumer promotion of prescription drugs: The case of COX-2 inhibitors. Acad Health Serv Res Health Policy Meet 19(41)
25. Coenen S, Michiels B, Renard D, Denekens J (2006) Antibiotic prescribing for acute cough: The effect of perceived patient demand. Br J Gen Pract 56(524):183-190
26. Triggle D (2005) Vaccines, viagra, and vioxx: Medicines, markets, and money - when life-saving meets life-style. Drug Dev Res 64:90-98
27. Cabana M, Rand C, Powe N, Wu A, Wilson M, Abboud P et al (1999) Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 282(15):1458-1465
28. McNamara C (2006) Basics of conducting focus groups. http://www.managementhelp.org/evaluatn/focusgrp.htm. Cited 15 Mar 2007
29. Romney A, Batchelder W, Weller S (1986) Culture as consensus: A theory of culture and informant accuracy. Am Anthropol 88:313-338
30. Carlsson F, Merlo J, Lindstrom M, Ostergren PO, Lithman T (2006) Representativity of a postal public health questionnaire survey in Sweden, with special reference to ethnic differences in participation. Scand J Public Health 34(2):132-139
31. Green C, Pope C (1999) Gender, psychosocial factors and the use of medical services: A longitudinal analysis. Soc Sci Med 48:1363-1372
32. Bertakis K, Azari R, Helms L, Callahan E, Robbins J (2000) Gender differences in the utilization of health care services. J Fam Pract 49(2):147-152
33. Robinson A, Thomson R (2001) Variability in patient preferences for participating in medical decision making: Implication for the use of decision support tools. Qual Health Care 10:i34-i38
34. Callahan CA, Hojat M, Gonnella JS (2007) Volunteer bias in medical education research: An empirical study of over three decades of longitudinal data. Med Educ 41(8):746-753
35. Greenbaum T (1998) The handbook for focus group research, 2nd edn. Sage, Thousand Oaks